Rare Disease AdvisorPediatric-Inspired Therapeutic Regimen May Be Beneficial in Adults with T-Cell ALL

⚠️ Small Study / Early Comparative Evidence

Treatment of adult T-cell ALL has historically been informed by pediatric regimens, but prospective comparative data in adults remain limited. This retrospective analysis from Princess Margaret Cancer Center examined 146 adult patients with T-cell ALL treated with a pegasparaginase-containing pediatric-inspired regimen between 2001 and 2024, with a median follow-up of 3.9 years, reporting survival outcomes and the prognostic impact of early T-cell precursor immunophenotype.

Clinical Considerations

• 3-year OS was 73% and leukemia-free survival 77% overall; outcomes stratified sharply by age, with 3-year OS of 81% in patients under 40, 67% in patients 40 to 60, and 47% in patients over 60
• Early T-cell precursor phenotype — present in 83% of the cohort — was not associated with worse OS or leukemia-free survival, challenging its use as an adverse prognostic marker in this treatment context
• Complete remission was achieved in 86% of patients; however, among those who relapsed, 3-year OS was 39%, underscoring persistently poor postrelapse outcomes despite frontline success
• 3-year cumulative incidence of relapse in complete remission patients was 22%, signaling a meaningful residual risk that current predictive tools do not adequately stratify

Practice Applications

• Recognize pediatric-inspired regimens as associated with favorable survival signals in adult T-cell ALL, particularly in patients under 60, while interpreting these findings as hypothesis-generating given single-center retrospective design
• Avoid using early T-cell precursor phenotype alone as a basis for treatment de-escalation or intensification decisions; this cohort did not demonstrate independent prognostic impact
• Monitor patients over 60 with heightened vigilance; this subgroup showed substantially worse survival and may warrant distinct therapeutic consideration or clinical trial enrollment
• Identify postrelapse management as the critical unmet need in this population; improved predictive tools and novel therapeutic approaches are needed before remission-stage gains translate to durable cure